The extent of Nf-L elevation in this model (~1.5-2 fold) was within the range of what has been reported in patients with mild-cognitive impairment and AD [101, 102] and contrasted with the profound elevation of Nf-L levels in CSF reported in the 5xFAD and APP/PS1 mouse models (~10-20 fold) [101, 102], indicating that AppSAA mice may better recapitulate the rate of neurodegeneration estimated in the human condition than the 5xFAD or APP/PS1 mouse models. The gene discussed is NEFL; the disease is Alzheimer disease.